Economic Evaluation of Sacituzumab Govitecan for the Treatment of Metastatic Triple-Negative Breast Cancer in China and the US

BACKGROUND: The effectiveness of Sacituzumab Govitecan (SG) for metastatic triple-negative breast cancer (mTNBC) has been demonstrated. We aimed to evaluate its cost-effectiveness on mTNBC from the Chinese and United States (US) perspective. METHODS: A partitioned survival model was developed to com...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Jigang, Han, Mingyang, Liu, Aihua, Shi, Bo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8581633/
https://www.ncbi.nlm.nih.gov/pubmed/34778047
http://dx.doi.org/10.3389/fonc.2021.734594

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8581633/
https://www.ncbi.nlm.nih.gov/pubmed/34778047
http://dx.doi.org/10.3389/fonc.2021.734594

Ejemplares similares